GAMMA Investing LLC Has $1.14 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,083 shares of the biopharmaceutical company’s stock after purchasing an additional 199 shares during the period. GAMMA Investing LLC’s holdings in Regeneron Pharmaceuticals were worth $1,138,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of REGN. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the period. Capital World Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares during the last quarter. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Putnam Investments LLC grew its position in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the period. Finally, Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $932,571,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on REGN shares. Barclays increased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Argus boosted their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,097.05.

Insiders Place Their Bets

In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock valued at $64,546,123 over the last three months. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $6.92 during midday trading on Monday, reaching $1,075.27. The stock had a trading volume of 297,001 shares, compared to its average volume of 469,345. The company has a current ratio of 5.96, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $118.48 billion, a price-to-earnings ratio of 31.97, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13. The company’s 50-day moving average is $1,043.43 and its 200 day moving average is $983.16. Regeneron Pharmaceuticals, Inc. has a 12-month low of $765.28 and a 12-month high of $1,115.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the firm posted $8.79 earnings per share. The business’s revenue was up 12.3% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.38 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.